1.Schweitzer, BI, Dicker, AP, Bertino, JR. Dihydrofolate-reductase as a therapeutic target. FASEB Journal 1990; 4: 2441–2452.
2.Baird, DT. Mode of action of medical methods of abortion. Journal of the American Medical Womens Association 2000; 55: 121–126.
3.Hernandez-Diaz, S, et al. Folic acid antagonists during pregnancy and the risk of birth defects. New England Journal of Medicine 2000; 343: 1608–1614.
4.Hernandez-Diaz, S, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. American Journal of Epidemiology 2001; 153: 961–968.
5.Czeizel, AE, Toth, M, Rockenbauer, M. Population-based case control study of folic acid supplementation during pregnancy. Teratology 1996; 53: 345–351.
6.Berry, RJ, et al. Prevention of neural-tube defects with folic acid in China. New England Journal of Medicine 1999; 341: 1485–1490.
7.Wald, N. Prevention of neural-tube defects – results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131–7.
8.Werler, MM, et al. Multivitamin supplementation and risk of birth defects. American Journal of Epidemiology 1999; 150: 675–682.
9.Yang, QH, et al. Does periconceptional multivitamin use reduce the risk for limb deficiency in offspring? Epidemiology 1997; 8: 157–161.
10.Czeizel, AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. American Journal of Medical Genetics 1996; 62: 179–183.
11.Botto, LD, et al. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: Results from a population-based, case-control study. Pediatrics 1996; 98: 911–917.
12.Smulders, YM, et al. Trimethoprim and fasting plasma homocysteine. Lancet 1998; 352: 1827–1828.
13.Goldberg, AB, Greenberg, MB, Darney, PD. Drug therapy: misoprostol and pregnancy. New England Journal of Medicine 2001; 344: 38–47.
14.Grimes, DA, Creinin, MD. Induced abortion: an overview for internists. Annals of Internal Medicine 2004; 140: 620–626.
15.UNAIDS. Provisional WHO/UNAIDS secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Geneva: UNAIDS; 2000.
16.Andersen, TF, et al. The Danish National Hospital Register – a valuable source of data for modern health sciences. Danish Medical Bulletin 1999; 46: 263–268.
17.Knudsen, LB. The Danish Fertility Database. Danish Medical Bulletin 1998; 45: 221–225.
18.The Danish National Board of Health. Project regarding data quality in the National Hospital Register [in Danish]. Copenhagen: The Danish National Board of Health; 2004.
19.Gaist, D, Sorensen, HT, Hallas, J. The Danish prescription registries. Danish Medical Bulletin 1997; 44: 445–448.
20.von Elm, E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.
21.Sorensen, HT, et al. Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. Journal of Medical Systems 1996; 20: 57–65.
22.Kumar, S. Occupational, environmental and lifestyle factors associated with spontaneous abortion. Reproductive Sciences 2011; 18: 915–930.
23.Di Prima, FA, et al. Antiphospholipid syndrome during pregnancy: the state of the art. Journal of Prenatal Medicine 2011; 5: 41–53.
24.Buss, L, et al. Spontaneous abortion: a prospective cohort study of younger women from the general population in Denmark. Validation, occurrence and risk determinants. Acta Obstetrica et Gynecologia Scandinavica 2006; 85: 467–475.
25.Stover, J, Fahnestock, M. Coverage of selected services for HIV/AIDS prevention, Care, and treatment in low- and middle-income countries in 2005. Washington, DC: Constella Futures, POLICY Project, 2006.
26.UNAIDS. Report on the global HIV/AIDS epidemic 2008. Geneva: UNAIDS; 2008.
27.Wiktor, SZ, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469–1475.
28.Nunn, AJ, et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. British Medical Journal 2008; 337: a257.
29.Mermin, J, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364: 1428–1434.